表观遗传学
背景(考古学)
酰肼
药品
计算生物学
药物发现
组蛋白脱乙酰基酶
疾病
药理学
化学
生物信息学
组蛋白
生物
医学
生物化学
基因
内科学
古生物学
有机化学
作者
Suvankar Banerjee,Sandip Kumar Baidya,Nilanjan Adhikari,Tarun Jha,Balaram Ghosh
标识
DOI:10.2174/1568026623666230405124207
摘要
Epigenetic modulations by HDACs are associated with multiple disease conditions. In this context, HDACs play vital roles in the progression of diseases including several cancers, neurodegenerative diseases, inflammatory diseases, and metabolic disorders. Though several HDAC inhibitors have been established as drug candidates, their usage has been restricted because of broad-spectrum inhibition, highly toxic character, and off-target adverse effects. Therefore, specific HDAC selectivity is essential to get rid of such adverse effects. Hydrazide-based compounds have already been proven to exert higher inhibitory efficacy and specific HDAC selectivity. In this article, the detailed structure-activity relationship (SAR) of the existing hydrazide-based HDAC inhibitors has been elucidated to gather crucial information that can be utilized further for the development of promising drug candidates for combating diverse diseases in the future.
科研通智能强力驱动
Strongly Powered by AbleSci AI